β-amyloid oligomers in aging and Alzheimer's disease

β-amyloid oligomers in aging and Alzheimer's disease

Alzheimer’s disease (AD) is a fatal neurodegenerative disorder, and the most common cause of dementia in the elderly. The cause of AD is not known, but genetic evidence strongly supports the hypothesis that pathological aggregation of the β-amyloid protein (Aβ) triggers the disease process. AD has...

Full description

Bibliographic Details
Main Authors:	Kathleen R. Zahs, Karen Hsiao Ashe
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-07-01
Series:	Frontiers in Aging Neuroscience
Subjects:	β-Amyloid Alzheimer’s disease oligomer Aβ*56 preclinical Alzheimer’s disease
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fnagi.2013.00028/full

Similar Items

Amyloid-β Oligomers: Multiple Moving Targets
by: Dylan Shea, et al.
Published: (2022-04-01)

The Toxicity and Polymorphism of β-Amyloid Oligomers
by: Ya-ru Huang, et al.
Published: (2020-06-01)

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease
by: Montserrat Serra-Batiste, et al.
Published: (2018-04-01)

Amyloid Beta Oligomers-Induced Ca<sup>2+</sup> Entry Pathways: Role of Neuronal Networks, NMDA Receptors and Amyloid Channel Formation
by: Erica Caballero, et al.
Published: (2022-05-01)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
by: Heinz Hillen
Published: (2023-01-01)

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
by: Yuan Zhang, et al.
Published: (2019-07-01)

Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease
by: Min Jeong Wang, et al.
Published: (2017-12-01)

Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain
by: Akiko Amano, et al.
Published: (2023-01-01)

ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
by: Grant A. Krafft, et al.
Published: (2022-04-01)

Challenges in understanding the structure/activity relationship of Aβ oligomers
by: Albert W. Pilkington IV, et al.
Published: (2019-01-01)

Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
by: Natalia Salvadores, et al.
Published: (2022-03-01)

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
by: Botond Penke, et al.
Published: (2020-04-01)

Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide
by: Jian-Xiang Zhang, et al.
Published: (2019-12-01)

Squalamine and Its Derivatives Modulate the Aggregation of Amyloid-β and α-Synuclein and Suppress the Toxicity of Their Oligomers
by: Ryan Limbocker, et al.
Published: (2021-06-01)

Cajaninstilbene Acid Ameliorates Cognitive Impairment Induced by Intrahippocampal Injection of Amyloid-β1–42 Oligomers
by: Li-Sha Wang, et al.
Published: (2019-09-01)

A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease
by: Shao-wei Wang, et al.
Published: (2017-06-01)

Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease
by: Xue Meng, et al.
Published: (2019-10-01)

The Toxicity of Amyloid ß Oligomers
by: Lock Yue Chew, et al.
Published: (2012-06-01)

Postsynaptic Receptors for Amyloid-β Oligomers as mediators of neuronal damage in Alzheimer's Disease
by: Margarita C. Dinamarca, et al.
Published: (2012-12-01)

The new β amyloid-derived peptide Aβ1–6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity
by: Luisa Diomede, et al.
Published: (2016-04-01)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
by: Philip S. Insel, et al.
Published: (2017-05-01)

Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease
by: Marcos J. Guerrero-Muñoz, et al.
Published: (2014-11-01)

Sleep deprivation aggravated amyloid β oligomers-induced damage to the cerebellum of rats: Evidence from magnetic resonance imaging
by: Wensheng Guo, et al.
Published: (2023-01-01)

The Role of Lipid Environment in Ganglioside GM1-Induced Amyloid β Aggregation
by: Vladimir Rudajev, et al.
Published: (2020-09-01)

Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study
by: Can Sheng, et al.
Published: (2022-02-01)

5-Hydroxycyclopenicillone Inhibits β-Amyloid Oligomerization and Produces Anti-β-Amyloid Neuroprotective Effects In Vitro
by: Jiaying Zhao, et al.
Published: (2017-10-01)

Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42
by: Seong Soo A. An, et al.
Published: (2017-10-01)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
by: Noelia Fandos, et al.
Published: (2017-01-01)

A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity
by: Travis Rush, et al.
Published: (2020-02-01)

Superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer’s Disease
by: Xiao-ge Liu, et al.
Published: (2020-11-01)

Frondoside A Attenuates Amyloid-β Proteotoxicity in Transgenic Caenorhabditis elegans by Suppressing Its Formation
by: Taweesak Tangrodchanapong, et al.
Published: (2020-09-01)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
by: Anne-Cathrine S. Vogt, et al.
Published: (2023-02-01)

Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn<sup>2+</sup> in cognitively intact aged individuals with Alzheimer’s disease neuropathology
by: Bjorklund Nicole L, et al.
Published: (2012-05-01)

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01)

Taxifolin inhibits amyloid-β oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy
by: Satoshi Saito, et al.
Published: (2017-04-01)

Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway
by: Catherine Malaplate-Armand, et al.
Published: (2006-07-01)

Pharmacological Potential of Cilostazol for Alzheimer’s Disease
by: Kenjiro Ono, et al.
Published: (2019-05-01)

Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer’s Disease
by: Marlene Pils, et al.
Published: (2023-05-01)

Intraneuronal amyloid β accumulation and oxidative damage to nucleic acids in Alzheimer disease
by: Akihiko Nunomura, et al.
Published: (2010-03-01)

Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
by: Terrone L. Rosenberry, et al.
Published: (2022-12-01)